Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene

pCDH-SFFV-GLuc-CreERT2-mCherry
(Plasmid #178185)

Ordering

Item Catalog # Description Quantity Price (USD)
Plasmid 178185 Standard format: Plasmid sent in bacteria as agar stab 1 $85

This material is available to academics and nonprofits only.

Backbone

  • Vector backbone
    pCDH
  • Backbone manufacturer
    System Biosciences
  • Total vector size (bp) 9792
  • Vector type
    Lentiviral

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    High Copy

Gene/Insert 1

  • Gene/Insert name
    GLuc
  • Insert Size (bp)
    797

Gene/Insert 2

  • Gene/Insert name
    CreERT2
  • Insert Size (bp)
    1970

Gene/Insert 3

  • Gene/Insert name
    mCherry
  • Insert Size (bp)
    681

Resource Information

Terms and Licenses

Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pCDH-SFFV-GLuc-CreERT2-mCherry was a gift from Irmela Jeremias (Addgene plasmid # 178185 ; http://n2t.net/addgene:178185 ; RRID:Addgene_178185)
  • For your References section:

    In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets. Carlet M, Volse K, Vergalli J, Becker M, Herold T, Arner A, Senft D, Jurinovic V, Liu WH, Gao Y, Dill V, Fehse B, Baldus CD, Bastian L, Lenk L, Schewe DM, Bagnoli JW, Vick B, Schmid JP, Wilhelm A, Marschalek R, Jost PJ, Miething C, Riecken K, Schmidt-Supprian M, Binder V, Jeremias I. Nat Commun. 2021 Sep 27;12(1):5655. doi: 10.1038/s41467-021-25963-z. 10.1038/s41467-021-25963-z PubMed 34580292